Search
Novo Nordisk Introduces $499 Monthly Pricing for Ozempic for Eligible US Patients
2025-08-19 /
Read about 0 minute
Author：小编
Novo Nordisk announced on Monday a new pricing strategy for its diabetes drug Ozempic, offering it to eligible self-pay patients with type 2 diabetes in the United States at a cost of $499 per month. This initiative is designed to address competition from generic drugs and the pressure exerted by a significant rival in the US market, Eli Lilly. Earlier in the month, Novo Nordisk had anticipated ongoing generic competition for its weight-loss drug Wegovy. Notably, both Ozempic and Wegovy share the active ingredient semaglutide. Novo Nordisk emphasized that this new pricing model is part of its ongoing commitment to enhance patient access to authentic semaglutide medications.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
